The groundbreaking rise of Viagra presented a considerable prospect for shareholders , but its patent has lapsed , creating a intricate landscape. Alternative versions have appeared in the space , diminishing sales and putting a squeeze on profit margins . While major drug companies maintain a foothold in this sector , the outlook looks ambiguous b